An announcement from Maravai Lifesciences Holdings ( (MRVI) ) is now available.
On March 20, 2025, Maravai LifeSciences Holdings announced its financial guidance for the full year 2025 during a conference call. The company expects its revenue for 2025 to range between $185.0 million and $205.0 million, with first-quarter revenue projected between $43.0 million and $45.0 million. The guidance includes anticipated expenses such as interest, depreciation, and stock-based compensation, and estimates capital expenditures between $15.0 million and $20.0 million. This announcement provides insights into Maravai’s expected financial performance and strategic planning for the upcoming year.
More about Maravai Lifesciences Holdings
Maravai LifeSciences Holdings operates in the life sciences industry, focusing on providing essential products and services that support the development of drug therapies, diagnostics, and novel vaccines.
YTD Price Performance: -55.74%
Average Trading Volume: 2,931,298
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $651.5M
See more data about MRVI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com